Your session is about to expire
← Back to Search
Fostamatinib + Paclitaxel for Ovarian Cancer
Study Summary
This trial is testing the safety of a combination of drugs for ovarian cancer patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer returned within 6 months after platinum treatment or I can't have more platinum therapy, and I haven't had weekly paclitaxel for it.I have moderate to severe nerve damage.My organs and bone marrow are functioning normally.I am not allergic to fostamatinib, paclitaxel, or similar drugs, or I can tolerate paclitaxel with a special protocol.I am not pregnant or breastfeeding.I have a confirmed diagnosis of ovarian, fallopian tube, or peritoneal carcinoma.My blood pressure is controlled and ≤ 140/90 mmHg.I am HIV-positive, on effective treatment, and my viral load is undetectable.My hepatitis B is under control with medication that's allowed in this trial.I haven't had chemotherapy or radiotherapy in the last 4-6 weeks and stopped hormonal therapy at least a week ago.My brain scans show no signs of cancer growth after treatment for brain metastases.I can provide a tumor sample before and after starting treatment, or I have a recent sample.I have recovered from side effects of previous treatments, except for conditions like hair loss.I can take pills by mouth.I had hepatitis C but am cured, or I'm being treated with an undetectable viral load.I can take care of myself but might not be able to do active work.Patients must have a way to measure their disease that follows a specific set of rules called RECIST v1.1.I am a woman aged 18 or older.I am not using strong CYP3A4 affecting drugs and will be cautious with moderate ones.You have had or currently have another type of cancer that will not affect the evaluation of the new treatment, and the study doctor gives permission.My heart function is classified as class 2B or better, despite my history of heart issues or treatments.I do not have untreated brain metastases.I do not have any uncontrolled illnesses.
- Group 1: Fostamatinib and Paclitaxel
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent has enrollment been successful for this clinical trial?
"Unfortunately, this clinical trial has concluded its recruitment process. It was initially uploaded on April 3rd 2018 and most recently updated the 8th of October 2022. Nevertheless, there are currently 677 studies enrolling patients with ovarian cancer and an additional 837 for Fostamatinib & Paclitaxel in search of participants."
How are Fostamatinib and Paclitaxel typically administered for therapeutic purposes?
"Fostamatinib and Paclitaxel are normally used to combat neoplasm metastasis, but they can also be employed for alleviating Kaposi Sarcoma, advanced directives, and fallopian tubes carcinoma."
To what extent have Fostamatinib and Paclitaxel been tested together in prior clinical studies?
"The first research of Fostamatinib and Paclitaxel was conducted back in 1997 at the City of Hope Comprehensive Cancer Center. Currently, there are 1175 completed clinical trials on record with 837 ongoing studies, many of which originate from Baltimore, Maryland."
What potential risks are associated with Fostamatinib and Paclitaxel treatments?
"Our experts at Power graded the safety and efficacy of Fostamatinib with Paclitaxel to be a 1, as this is still an experimental phase. Therefore, there is limited supporting data available for both drug's effects."
Are researchers still enrolling individuals into this research project?
"This trial has concluded its recruitment process. Initially published on April 3rd 2018, the study received its last update on August 10th 2022. However, if you are still searching for trials to participate in, there are 677 studies actively looking for ovarian cancer patients and 837 studies recruiting participants for Fostamatinib/Paclitaxel treatments."
Is this research limited to individuals of a certain age, or can people under 35 years old join?
"According to the trial's entry requirements, successful applicants must be aged between 18 and 100. There are 48 trials specifically for those under 18 years of age and 1484 categories available for individuals over 65."
What criteria is necessary for individuals to be eligible to join this research project?
"This research endeavour is in need of 27 individuals with ovarian cancer between the ages 18 and 100. Eligibility necessitates that patients present measurable disease according to RECIST v1.1; have relapsed within 6 months of last platinum-containing regimen or unable to proceed with more platinum therapy, possess normal organ and marrow function, maintained blood pressure ≤ 140/90 mmHg., not pregnant or planning on becoming pregnant during trial period - utilizing adequate contraception (hormonal or barrier method birth control; abstinence). Lastly, a Karnofsky ≥60% rating should be attained as per Appendix A standards."
Share this study with friends
Copy Link
Messenger